Arkema


Sustained profitability despite lower sales prices

14/05/24 -"Sales in the Q1 declined as anticipated, but adjusted EBITDA demonstrated greater resilience. The figures were mixed compared to the consensus (sales: -2.0%; adjusted EBITDA: +2.6%; adjusted EPS: ..."

Pages
63
Language
English
Published on
14/05/24
You may also be interested by these reports :
28/09/26
BASF is looking to consolidate its lead in chemicals by acquiring Evonik. The appeal lies in portfolio adjacency, principally in Materials and ...

23/09/26
Johnson Matthey (UK, Reduce) has spent the past few years doing what many industrial conglomerates eventually do: shedding parts of itself until only ...

23/09/26
Weak FY25/26 results (below expectations) – Solid outlook on FY26/27E

08/09/26
Wacker’s polysilicon business has been under pressure for years now, given Chinese overcapacity. Semis have been the growth engine, partly offsetting ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO